Skip to main content

Table 1 Clinical-pathological features of Cohort I pLGG patients

From: MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

Cohort I pLGG patients
Sample code Age (years) Gender Site of onset Histology Type of resection Progression Progression Free Survival (years) Overall Survival (years) Mutational status of BRAF Profiling (P) / ddPCR (d)
22233 5 M H Supra DNET NTR WITH 2 9 NA P + d
OPBG13P 4 F H Supra DNET NTR WITH 4.4 8 WT P
16526 13 F H Supra GG NTR WITH 7 8 V600E P + d
19683 12 F H Supra GG NTR WITH 2 9 WT* P + d
22457 9 M H Supra GG NTR WITH 7 10 V600E P + d
11364 12 M H Supra GG NTR WITH 5 10 WT* P + d
25,595 4 M H Supra PA NTR WITH 1 NA WT* P + d
11720 2 M H Supra PA NTR WITH 2 NA WT* P + d
8380 16 F H Supra PA NTR WITH 2 12 WT* P + d
21617 6 M H Supra PA NTR WITH 5 13 WT* P + d
256 13 3.6 M Md Supra PA NTR WITH 0.58 7 K15B9 P + d
OPBG45C 7 F Md Supra GG Biopsy WITH 4 7 WT P + d
OPBG62P 3.7 M Md Supra GG Biopsy WITH 0.5 5 WT P + d
OPBG51S 6.8 F Md Supra PA NTR WITH 0.66 5 K16B11 P + d
119637 FF 6 M Md Supra PA NTR WITH 1.58 14 K16B9 P + d
179435 FF 6 M Md Supra PA NTR WITH 4.25 17 K16B9 P + d
177408 FF 6 M Md Supra PA NTR WITH 0.75 12 WT* P + d
123965 FF 8 F Md Supra PA NTR WITH 2.08 16 K15B9 P + d
89636 FF 2 F Md Supra PA NTR WITH 9.33 25 WT* P
117945 FF 0.91 M Md Supra PA NTR WITH 1.83 17 WT P + d
OPBG135F 7 M Md Supra PA Biopsy WITH 0.5 1.66 WT* d
1651 13 M H Supra AG NTR W/O 8 8 WT* P + d
OPBG54M 8 F H Supra DNET NTR W/O 5 5 WT P + d
OPBG74M 5 F H Supra DNET NTR W/O 2.16 2.16 WT* P + d
OPBG112I 14 F H Supra GG NTR W/O 0.33 0.33 V600E d
OPBG94C 5.3 F Md Supra PA NTR W/O 1 1 WT* P + d
OPBG43D 3 M Md Supra PA NTR W/O 3.75 3.75 K16B9 P + d
OPBG58SP 5 M Md Supra PA NTR W/O 3 3 WT P + d
172524 FF 14 M Md Supra PA NTR W/O 12 12 WT* P + d
45723 FF 16 F Md Supra PA NTR W/O 17 17 V600E P + d
75683 FF 7 M Md Supra PA NTR W/O 16 16 WT* P + d
OPBG99D 10 M Md Supra GNT NTR W/O 0.91 0.91 V600E d
OPBG115C 7 F Md Supra PA Biopsy W/O 0.33 0.33 K15B9 d
OPBG117C 10 F Md Supra GG Biopsy W/O 0.5 0.5 WT d
  1. H Hemispheric, M Midline, DNET Dysembryoplastic Neuropepithelial Tumor, GG Ganglioglioma, GT Glioneuronal Tumor, PA Pilocytic Astrocytoma, AG Angiocentric Glioma, NTR Near Total Resection, WITH With progression, W/O Without progression, CR Complete remission, DoD Dead of Disease, SD Stable Disease, PR Partial Remission, NA Not applicable, ND Not detected. BRAF screening was limited to the V600E point mutation and three fusion genes [KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), KIAA1549-BRAF exon 15-exon 9 (K15B9)]. WT* = Not screened for BRAF K15B9